Clinical Trial Update: Study of HBI0101 (NXC-201) CAR-T Therapy in Multiple Myeloma and Light-Chain Amyloidosis [Phase 2]

View source ↗

Summary

This phase 2 study is evaluating the CAR-T therapy HBI0101 (NXC-201) in patients with multiple myeloma (refractory or relapsed) and light-chain (AL) amyloidosis…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Light-chain Amyloidosis
• Multiple Myeloma

Drugs mentioned

• HBI0101 (NXC-201) CAR-T Therapy (NXC-201)

Snippet

Sponsor: Polina Stepensky | Conditions: Multiple Myeloma, Refractory to Standard Treatment, Multiple Myeloma, Relapsed | Phase 2 | Status: RECRUITING